1. Is Transgene Biotek Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Transgene Biotek Ltd is a below average quality company.
2. Is Transgene Biotek Ltd undervalued or overvalued?
The key valuation ratios of Transgene Biotek Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Transgene Biotek Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Transgene Biotek Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||-0.6%||-19%||-9.3%||-11.9%||-17.2%||-15.2%||-24.7%||-35.3%||-49.5%||-73.7%||-|
|Value Creation Index ⓘ||-1.0||-2.4||-1.7||-1.9||-2.2||-2.1||-2.8||-3.5||-4.5||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||-93.5%||-68.4%||-41.9%||55.6%||-57.1%||-41.7%||-100%||NA||-47.1%||-|
|Adj EPS ⓘ||-0.3||-7||-2.5||-2.8||-2.6||-1.1||-1.3||-1.5||-1.4||-1.4||-1.1|
|YoY Gr. Rt. %||-||NA||NA||NA||NA||NA||NA||NA||NA||NA||-|
|BVPS (₹) ⓘ||49||26||23.5||20.4||5.5||4.6||3.4||2||0.6||-0||-0.4|
|Adj Net Profit ⓘ||-2||-52.8||-19||-21.5||-19.9||-8.5||-10||-11||-10.4||-10.4||-8|
|Cash Flow from Ops. ⓘ||99.6||-2.1||-1||0||0||-0.6||-1.7||0.1||0||0.1||-|
|Debt/CF from Ops. ⓘ||0.2||-6.2||-15.2||818||692.9||-15.8||-5.3||74.1||901.5||125.2||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||NA||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||-0.6||-20.3||-10.1||-12.9||-20.3||-22.2||-33||-53.3||-105.6||-465.8||468.1|
|Op. Profit Mgn % ⓘ||-5.6||-185.4||-480.9||-623.1||-910.9||-1779.2||-944.2||-24147.1||-307.2||-531.8||-155.2|
|Net Profit Mgn % ⓘ||-13.2||-5376.3||-6047.7||-11864.4||-7071.7||-7161.3||-14076||-306601.7||-6153.4||-11998.4||-5953.4|
|Debt to Equity ⓘ||0.1||0.1||0.1||0.1||0.4||0.3||0.4||0.7||2.4||-61||-|
|Working Cap Days ⓘ||4,090||28,752||87,392||1,34,729||54,937||75,086||1,21,127||24,16,578||51,163||1,00,234||0|
|Cash Conv. Cycle ⓘ||56||6,555||19,843||18,102||1,132||155||172||3,537||52||234||0|
Return on Equity has increased versus last 3 years average to 468.10%
Sales growth is good in last 4 quarters at 150.00%
Sales growth has been subdued in last 3 years 0.00%
|TTM EPS (₹)||-1.1||-1.1|
|TTM Sales (₹ Cr.)||0.1||0.1|
|BVPS (₹.) ⓘ||-0.4||1.9|
|Reserves (₹ Cr.) ⓘ||-79||-62|
|From the Market|
|52 Week Low / High (₹)||2.65 / 4.41|
|All Time Low / High (₹)||0.10 / 322.50|
|Market Cap (₹ Cr.)||21.6|
|Equity (₹ Cr.)||75.8|
|Face Value (₹)||10|
|Industry PE ⓘ||60|
Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.
From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others.
In line with its expanded product development portfolio, Transgene is modifying its existing infrastructure to cater to further Research & Development activities and is presently constructing a new manufacturing facility to meet WHO and US FDA standards. Transgene is focused on maximizing synergies through strategic partnerships. We are excited to explore opportunities with partners and catalyze technological advances in the field of biotechnology. Since 1994, Transgene Biotek has developed or has been involved in the development of technology for several different bio-pharmaceuticals, recombinant vaccines and therapeutics. We have extensive experience and expertise to assist you in recombinant drug development, characterization, testing and validation.
Product range of the company includes:
The company is engaged in manufacturing drugs for:
New Drug Delivery System (NDDS)